HealthQuill Obesity Drugs
Novo Nordisk, a Danish pharmaceutical multinational, will invest $4.1 billion to build a new factory in the US to make obesity and chronic disease drugs, according to a company statement.
Drugs Health Pharma

Novo Nordisk to set up $4.1 billion injectables facility in US’s North Carolina

Novo Nordisk, a Danish pharmaceutical multinational, will invest $4.1 billion to build a new factory in the US to make obesity and chronic.

Read More
US-based Pacific Northwest National Laboratory, Microsoft Corp., and Micron Technology have joined hands to make computational chemistry available to researchers and industrial users.
Drugs Health Pharma

Roche forays into weight-loss therapy, buys Carmot for $2.7 billion

HQ Team December 4, 2023: In a strategic push into the obesity and diabetes treatment market, Roche, a leading pharmaceutical company, has finalized.

Read More
Pfizer Inc., has discontinued its clinical trials of the twice-daily oral weight-loss drug, danuglipron, after more than 50% of the patients opted out due to adverse effects of the medicine.
Drugs Health Pharma

Pfizer Inc., stops twice-daily oral obesity drug trial at mid-stage

HQ Team December 2, 2023: Pfizer Inc., has discontinued its clinical trials of the twice-daily oral weight-loss drug, danuglipron, after more than 50%.

Read More
X